Rahul Aggarwal
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (109)
Plasma concentration for copanlisib (BAY 80-6946). Plasma concentration of copanlisib (BAY 80-6946) was measured in samples from nine patients collected on cycle 1 day 15 before infusion (pre-dose) and at 0.5, 1, 2, 4, 6, 8, and 24 hours after infusion. Eight patients received copanlisib 45 mg and one patient received 30 mg. The time to the maximum concentration of copanlisib when administered in combination with rucaparib ranged between 0.5 and 4 hours. The mean terminal half-life was 41.4 ± 56.7 hours. The mean clearance was 32,656 ± 18,164 mL/hour. These parameters are consistent with historical PK parameters of copanlisib.
Year:
2025
Purpose: Metastatic castration-resistant prostate cancer with homologous recombination (HR) deficiency (HRD) is sensitive to PARP inhibitors (PARPi). PI3K inhibitors (PI3Ki) sensitize to PARPi by disrupting HR in preclinical models. This phase Ib/II study investigated copanlisib (Copa; pan–class I PI3Ki) and rucaparib (R). Patients and Methods: Eligible patients had metastatic castration-resistant prostate cancer treated with ≥1 androgen receptor inhibitor and taxanes. Phase I followed a standard 3 + 3 dose-escalation design (rucaparib 400–600 mg orally twice a day; Copa 45–60 mg i.v. on days 1, 8, and 15). Primary goal of phase I was to establish MTD and the recommended phase II dose. The primary endpoint of phase II was PSA50 response rate. Results: Thirteen patients enrolled had a median age of 64 (55–78) years and PSA was 11.7 ng/mL (0.018–2,101). Seven patients received taxanes, and one patient received PARPi. Eight patients had HRD+ tumors [ BRCA2 (four), BRCA1 (one), RAD51C (one), CDK12 (one), and FANCA (one)] and three had PTEN loss. There were two dose-limiting toxicities in dose level 1 (rucaparib 400 mg twice a day; Copa 45 mg on days 1, 8, and 15): grade 3 rash and aspartate aminotransferase/alanine aminotransferase elevation. Treatment-related adverse events ≥ grade 2 included leukopenia (54%), anemia (38%), rash (30%), fatigue (23%), and neutropenia (23%). Six patients were treated at dose level –1 without dose-limiting toxicities, which was established as the recommended phase II dose (rucaparib 400 mg twice a day + Copa 45 mg on day 1/15). Among patients with HRD+, one had confirmed partial response and three had stable disease by RECIST, including one patient treated with prior PARPi, and three patients had PSA50 responses (23%). Conclusions: Copa/R had an acceptable safety profile with a signal of efficacy supporting future studies of PARPi with PI3Ki. Significance: Gene alterations in the PI3K and HR pathways are common in prostate cancer. Based on preclinical studies, the inhibition of PI3K disrupts HR, and PARP blockade induces AKT activation, supporting the combination of PI3Ki and PARPi. Herein, we investigated the safety and preliminary efficacy of the PI3Ki copanlisib and the PARPi rucaparib in patients with or without alterations in HR repair pathway genes.
Year:
2025
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
Year:
2025
Hierarchical clustering analyses of benign, localized, and mCRPC tumors representing the expression of neuroendocrine marker genes (NE), androgen-related genes (AR), and genes related to squamous (SQUAM) differentiation
Year:
2025
Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.
Year:
2025
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
Year:
2025
Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.
Year:
2025
Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.
Year:
2025
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
Year:
2025
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (65)
Meng Zhang
Assistant Professor of Urology
Emory University
Rohit Mehra
University of Michigan Medical School
Benedito A. Carneiro
-
David A. Quigley
Assistant Professor
University of California, San Francisco
Sheldon Holder
Assistant Professor
Brown University
Mehmet Asim Bilen
Emory University School of Medicine
Joshua Lang
Professor
University of Wisconsin-Madison
Nancy Y. Greenland
-
Wendy Rathmell
Professor, Department Chair
Vanderbilt University Medical Center
Tamara L. Lotan
Professor
Johns Hopkins University
Jiaoti Huang
Professor and Chairman
Duke Medicine
Emily K. Bergsland
University of California, San Francisco
Nikolaos Trikalinos
Assistant Professor
Washington University in St. Louis
Alan Ashworth
University of California, San Francisco
Alexander W. Wyatt
Assistant Professor
The University of British Columbia
Matthew Rettig
Professor
University of California, Los Angeles
Shuang G. Zhao
University of Wisconsin-Madison
Massimo Loda
Chair
Weill Cornell Medical College
Lawrence True
Professor
University of Washington
Li Zhang
Professor
UCSF
Emily Chan
Stanford University
Timothy Burns
Professor
University of Pittsburgh
Henry VanBrocklin
Professor/ Director of Radiopharmaceutical Research
University of California, San Francisco
Kim Chi
Chief Medical Officer
BC Cancer
Jiang He
Professor
University of Virginia
David M. Wilson
University of California
Devalingam Mahalingam
Associate Professor of Medicine
Northwestern University Feinberg School of Medicine
Adam Olszewski
Associate Professor of Medicine
Rhode Island Hospital
Michelle Badura
Lecturer
Santa Clara University
Michael Haffner
Fred Hutchinson Cancer Research Center
Patricia LoRusso
Yale University
Renuka Sriram
University of California
Raunak Shrestha
Assistant Professor
Uniformed Services University of the Health Sciences
Lisa Horvath
Conjoint Professor of Medical Oncology (Genitourinary Cancer)
University of Sydney
Tomasz Michal Beer
Oregon Health & Science University
Emily Egusa
University of California, San Francisco
Chien-Kuang Ding
Assistant Professor
University of California, San Francisco
Anil Parsram Bidkar
Assistant Professional Researcher
University of California, San Francisco
Eric J. Small
University of California, San Francisco
Franklin W. Huang
-
Lawrence Fong
Fred Hutch Cancer Center
Owen Witte
University Professor
University of California, Los Angeles
Pamela N. Munster
Professor
Stanford University
Brandon Chen
University of California, San Francisco
Jeffrey Belkora
Associate Adjunct Professor
University of California, San Francisco
Mark A. Rubin
Professor
University of Bern
Arian Lundberg
Assistant Professor at KTH Royal Institute of Technology
KTH Royal Institute of Technology
Jonathan Chou
Assistant Professor
University of California, San Francisco
sinan wang
Assistant Professor
University of California, San Francisco
Felix Y. Feng
University of California
Changhua Mu
Assistant Professional Researcher
University of California, San Francisco
Christopher Evans
Professor
University of California, Davis
Ana Aparicio
Professor
The University of Texas MD Anderson Cancer Center
Wafik S. El-Deiry
Associate Dean, Oncologic Sciences
Brown University
Robert R. Flavell
University of California
Mathieu Lupien
Senior Scientist
University Health Network
Shahneen Sandhu
-
Peter S. Nelson
Fred Hutchinson Cancer Research Center
Y. Seo
University of California, San Francisco
Terence Friedlander
University of California, San Francisco
Megha Basak
University of California, San Francisco
Scott C. Kogan
University of California, San Francisco
kondapa Naidu Bobba
Assistant professor
University of Tennessee
Mamta Parikh
Associate Professor
University of California Davis Comprehensive Cancer Center
Shaolei Lu
Brown University Warren Alpert Medical School
Make your next move.
Prepare your application
Review drafts before you send them.